Kristina Lundberg

Translational cancer immunotherapy group

Cancer will affect every second individual in the coming years. The focus of my research is to utilise the immune system to eradicate tumours, since unharnessing this system has shown tremendous effects for cancer therapy.

Consequently, we identify and implement novel drug targets that enable the immune system to eradicate cancer cells so that more patients can benefit from immuno-oncological treatments and experience an improved survival.

T-cells

We focus on T-cells and their capacity to orchestrate an immune response against tumour cells and on cells that regulate T-cell activity, such as myeloid cells. Furthermore, we explore immune cell and cancer cell targets for combining cancer immunotherapy and radiation. Through a network of national and international collaborators we explore several different cancer indications, including acute myeloid leukaemia, bladder cancer and lung cancer.

Group of smiling people in green surroundings. Photo. — The Translational cancer immunotherapy group. Photo: Corinna Richter

Principal Investigator